

08/962, 027

- 53 -

**INTERMEDIATE RELEASE NICOTINIC ACID COMPOSITIONS FOR
TREATING HYPERLIPIDEMIA HAVING UNIQUE C_{max}, T_{max} and AUC
BIOPHARMACEUTIC CHARACTERISTICS**

5

Abstract

10

Intermediate release nicotinic acid formulations having unique biopharmaceutical characteristics, such as C_{max}, T_{max} and AUC, which are suitable for oral administration once per day during the evening or at night for treating hyperlipidemia without causing drug-induced hepatotoxicity to such a level that requires the therapy to be discontinued, are disclosed. The intermediate nicotinic acid formulations can be administered as tablets in dosage strengths of, for example, 375mg, 500mg, 750mg and 1000mg.